FDA Clears Creative Medical's Olastrocel Trial Expansion, Paving Way for Phase 3 in Back Pain
CELZ sits 56% above its 52-week low of $1.504.
Summary
Creative Medical Technology Holdings received FDA clearance to expand its ADAPT clinical trial for Olastrocel (CELZ-201) in chronic lower back pain, adding a new cohort of 15 patients. This follows positive interim 180-day data from the original study, which showed significant improvements in pain and functional disability. The company is now actively preparing for Phase 3 discussions with the FDA, a crucial advancement for this clinical-stage biotech, especially given its recent financial reports of zero revenue. Enrollment for the expansion cohort is already over 85% complete and is expected to finish by late summer 2026.
At the time of this announcement, CELZ was trading at $2.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.2M. The 52-week trading range was $1.50 to $6.25. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.